Unleashing the Power of Health Data
summary
Finland’s Findata already issues about 1800 permits, supports roughly 900 researchers across ~150 projects and runs 10 mandated secure processing environments, using metadata catalogs plus pseudonymization/anonymization to deliver extracted datasets for research (case studies: ICan biobank work with Boehringer Ingelheim, long-running FinDiane publications). Novartis frames the problem as a 12‑year, 90% failure drug development pipeline and proposes using linked real‑world data, digital twins and targeted trial emulation if the European Health Data Space delivers harmonized rules by 2029.
AI-written summary · about
chapters (9)
- 0:00European health data space
- 2:06Findata’s role in Finland
- 6:46Novartis on drug development
- 10:36Building national health authorities
- 12:46Data ownership debate in Germany
- 14:33Value from health data
- 16:40Finnish health data regulation
- 18:47Regulation vs innovation
- 20:32Homework for 2036
related talks
01h 17mSECONDARY USE OF PERSONAL DATA FOR (BIOMEDICAL) RESEARCH
21mExperiences from the Finnish Kanta PHR Ecosystem
28mData 4 Development
05mHadoop and Healthcare
21mShaping the future of health: Boehringer Ingelheim's Data & AI Journey
54mPlenary Session
31mAI in healthcare: Data driven transformation
19mThe Medical Informatics Initiative Germany